Prognostic stratification and minimal residual disease assessment in Acute Myeloid Leukemia by molecular techniques
Journal Title: Αρχεία Ελληνικής Ιατρικής - Year 2013, Vol 30, Issue 5
Abstract
Currently cytogenetic analysis at diagnosis provides the most important information about the prognosis of Acute Myeloid Leukemia (AML), with categorization into three distinct prognostic groups (favorable, intermediate and unfavorable). In favorable prognosis AML, specific fusion genes (PML/RARα, AML1/ETO, CBFβ/MYH11) are present. Both conventional cytogenetic analysis and molecular biology techniques contribute to the identification of these genetic lesions. The majority of patients with AML patients belong to the intermediate prognosis group and most of these (about 45% of all cases of AML) carry a normal karyotype at diagnosis, Cytogenetically Normal AML (CN-AML). In recent years, various gene mutations (FLT3, NPM1, CEBPA, MLL, N-RAS, RUNX1, WT-1, IDH) and forms of deregulated gene expression (WT-1, EVI1, PRAME, BAALC, ERG, MN-1) have been identified, illustrating enormous heterogeneity in the CN-AML subset. The prognostic relevance of FLT3 Internal Tandem Duplication (FLT3/ITD), NPM1 mutations and CEBPA biallelic mutations in the CN-AML subset has been documented, and these genetic lesions are currently used for prognostic classification. In studies on patients with t(8;21) AML specific gene mutations (c-KIT, N-RAS, FLT3) have been identified. The c-KIT mutations, identified mainly in exon 8, were found to be associated with an adverse prognosis. Monitoring the Minimal Residual Disease (MRD) after consolidation chemotherapy in patients with AML is important for assessing the risk of relapse. Real time Quantitative Polymerase Chain Reaction (RQ-PCR) analysis has in most instances the sensitivity to detect at least one leukemic cell in 104 background cells. Standardized RQ-PCR procedures have now been developed for the most common types of fusion transcripts (PML/RARα, AML1/ETO and CBFβ/ MYH11) present in AML, allowing large scale MRD studies. In addition, a reliable and highly sensitive RQ-PCR test can be performed in almost 90% of patients with NPM1 mutations (about 35% of all cases of AML, and RQ-PCR assessment of disease level is, through the use of WT-1 overexpression, now feasible in more than 70%.
Authors and Affiliations
I. KAKKAS
Keywords
Related Articles
- EP ID EP115288
- DOI -
- Views 71
- Downloads 0
Development and psychometric assessment of a Greek-language inpatient satisfaction questionnaire
OBJECTIVE Τhe primary research aim of this study was to develop a reliable and valid instrument for the measurement of inpatient satisfaction. METHOD A questionnaire was created by means of literature review, on-site...
Favism A brief history from the "abstain from beans" of Pythagoras to the present
Favism is a form of hemolytic anemia and jaundice following the intake of fava beans and other legumes and various drugs. It is caused by a hereditary abnormality of the red cell enzyme glucose-6-phosphate dehydrogenase...
Role of research in mycology in the introduction of fungal infection determinants
In recent years a multitude of molecular and immuno-serological methods have been introduced in the field of diagnostic mycology. Rapid developments in the area referred to as "molecular diagnosis of fungal diseases", ge...
Hepatosplenomegaly in a patient with rheumatoid arthritis treated with methotrexate
The case is reported of a 79 year-old female with rheumatoid arthritis, receiving treatment with methotrexate, who presented with hepatomegaly, splenomegaly, leukopenia and hypergammaglobulinemia. The diagnosis of viscer...
The diagnosis and treatment of hypoglycemic syndrome
The issue of hypoglycemia is a common problem in everyday clinical practice and many individuals visit primary health care services with the self-diagnosis of hypoglycemia in need of medical assistance. In most cases thi...